We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 12,026.00 | 12,006.00 | 12,012.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.26 | 186.15B |
From Apr 2019 to Apr 2024
Le laboratoire pharmaceutique britannique AstraZeneca (AZN.LN) a annoncé mercredi avoir conclu un accord sur la vente d'une partie de son activité d'antibiotiques à Pfizer pour près de 1,58 milliard de dollars, plus les royalties.
Dans le cadre de cet accord, Pfizer effectuera un paiement initial de 550 millions de dollars à AstraZeneca puis un versement de 175 millions de dollars en janvier 2019, sans condition. En fonction des résultats commerciaux des médicaments concernés, le géant américain pourra payer à AstraZeneca jusqu'à 850 millions de dollars, plus les royalties.
-Denise Roland, Dow Jones Newswires
(Version française Aurélie Henri) ed : LBO
(END) Dow Jones Newswires
August 24, 2016 02:56 ET (06:56 GMT)
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
